about
sameAs
Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myelomaImmunoglobulin free light chains and solitary plasmacytoma of boneImmunoglobulin Light-Chain Amyloidosis: From Basics to New Developments in Diagnosis, Prognosis and TherapyDiagnosis, Prognosis, and Therapy of Transthyretin AmyloidosisImmunoglobulin light chain amyloidosis: 2013 update on diagnosis, prognosis, and treatmentSmoldering multiple myeloma requiring treatment: time for a new definition?Identification of copy number abnormalities and inactivating mutations in two negative regulators of nuclear factor-kappaB signaling pathways in Waldenstrom's macroglobulinemiaGene-expression profiling of Waldenstrom macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myelomaWaldenström macroglobulinemia: a review of therapy6q deletion discriminates Waldenström macroglobulinemia from IgM monoclonal gammopathy of undetermined significanceDiagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelinesLong-term survival in Waldenstrom macroglobulinemia: 10-year follow-up of Southwest Oncology Group-directed intergroup trial S9003.Cold agglutinin diseaseWorsening of congestive heart failure in amyloid heart disease treated by calcium channel-blocking agentsImproved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research StudyAnalysis of somatic hypermutation and antigenic selection in the clonal B cell in immunoglobulin light chain amyloidosis (AL).What is the correct philosophy for the treatment of multiple myeloma?Utility of Doppler myocardial imaging, cardiac biomarkers, and clonal immunoglobulin genes to assess left ventricular performance and stratify risk following peripheral blood stem cell transplantation in patients with systemic light chain amyloidosiPrimary localized amyloidosis of the bladder: experience with dimethyl sulfoxide therapy.Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis.Posttransplantation thrombotic thrombocytopenic purpura: a single-center experience and a contemporary review.Prognostic model for disease-specific and overall mortality in newly diagnosed symptomatic patients with Waldenstrom macroglobulinaemia.The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis.Caring for the terminally ill patient with hematologic malignancies.Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma.Thrombotic microangiopathy during peripheral blood stem cell mobilization.Lenalidomide plus dexamethasone vs. lenalidomide plus melphalan and prednisone: a retrospective study in newly diagnosed elderly myeloma.Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma.Waldenström macroglobulinemia: 2011 update on diagnosis, risk stratification, and management.Waldenström macroglobulinemia.Waldenström macroglobulinemia: 2012 update on diagnosis, risk stratification, and management.Waldenström macroglobulinemia: my way.Waldenström macroglobulinemia: 2013 update on diagnosis, risk stratification, and management.Long-term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom Macroglobulinemia.Refractory atypical hemolytic uremic syndrome with monoclonal gammopathy responsive to bortezomib-based therapy.Waldenström macroglobulinemia: 2015 update on diagnosis, risk stratification, and management.Waldenström macroglobulinemia: 2017 update on diagnosis, risk stratification, and management.Pomalidomide, Bortezomib and Dexamethasone (PVD) for Patients with Relapsed, Lenalidomide Refractory Multiple Myeloma.Conflicts of interest, authorship, and disclosures in industry-related scientific publications.Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients.
P50
Q24650785-21EA0324-FD52-4246-B128-7E2F711EF976Q24685868-7632B89F-C24B-413E-9E81-358DBDFDB0D9Q26771690-60998E4C-82B6-4BB1-BFE8-CAFF198DE78FQ26776496-F15DEAFA-BD61-4FA6-A01B-E2661780C67FQ26827340-52D4C10F-9565-45F9-8B64-FFDF783205BBQ26996579-66C48E17-2F45-4514-94E5-776D5181B35CQ28240713-22F725F2-8B91-40B6-831A-E4920E667CEEQ28248800-C0D50B1D-1C29-47A8-8870-8928153CC412Q28254008-37027E3E-4450-4482-B0E9-8FCE9CCB5C2FQ28260593-4E6DB19C-EF80-4EA0-AA6C-F77C5F280885Q28290236-3D22D3FF-0303-44CF-8286-B7C65C4A4CB0Q28297940-DFC08DD5-7348-4C60-98F7-96DA13DC7665Q28305182-7A474980-C143-4E96-A951-EAF02A0E4E1BQ29039877-DE6541E1-21BA-4F97-81AA-8D490EDEFB8EQ30278687-CF44D167-7472-4868-87C9-80D5FE7BD8A9Q30341660-1589B4EA-F86F-4AB8-96F5-06051E913991Q30366357-524E6E5C-3A76-4BBE-B9B7-CC2C0B7B3F56Q30469018-39DFAFE0-1F61-494D-8D24-27C4D646A917Q30843930-677B63D9-A895-488D-AA66-5B3E8DCBC0DFQ33151135-8A85C800-680A-4478-A827-4ABCF8E95061Q33347394-0E8B8FF3-CED0-4A41-82E9-05ACEB5ACE2DQ33370834-D94C983E-75AA-446A-BC42-36A5B6139CE8Q33372805-8BD0BE7E-3E8C-4F84-BE05-20A10CA40FB5Q33384013-FC85B90F-7EAE-4C0C-8B06-C9B5C1CB4F11Q33386052-DA51737C-A49E-4FA9-B6CA-E3E9ECFF1B9AQ33386887-9321AACD-3FCB-4530-9FEA-2407F6F160DBQ33389606-A7BF4601-1788-4438-96E4-6892C86EBDE3Q33390873-7080940B-AA79-4C7A-AF5A-C6083B9EC8E9Q33395066-6EDE07BE-5E70-4959-94F6-3C7E6C7B6384Q33400766-7C6F0E82-34DA-4405-A79E-04D0AE251D29Q33400780-F0995750-3316-4C31-B8E8-2641CB50869DQ33402669-3560D44E-9B7D-49AC-AAFB-59BB33B31AAFQ33408517-D6C12E7C-BBBF-4DD7-A121-F30622CDFBB9Q33414529-8D48FFD2-2950-4544-9010-A34DE7590494Q33418384-FC46EE50-2B1D-449C-8326-EBF6159DA5ECQ33421444-549FED36-51BC-4C5F-BD0E-CA111DEB84DFQ33438490-20D9BF74-5B85-464E-A918-5DA75EC05048Q33443411-510A7596-EEBA-4EA9-B3C0-3434D0E6FE3EQ33620440-1D5B9F29-ACF2-47A5-9101-FC001F1F2CE7Q33680252-954D8E35-3BB4-4C7B-955C-01BEA68E2811
P50
description
Narozen 7. 8. 1952, internista, hematolog, publikuje v oboru.
@cs
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Morie A Gertz
@ast
Morie A Gertz
@en
Morie A Gertz
@es
Morie A Gertz
@nl
Morie A. Gertz
@cs
Morie A. Gertz
@de
Morie A. Gertz
@sk
type
label
Morie A Gertz
@ast
Morie A Gertz
@en
Morie A Gertz
@es
Morie A Gertz
@nl
Morie A. Gertz
@cs
Morie A. Gertz
@de
Morie A. Gertz
@sk
altLabel
Morie A. Gertz
@en
Morie A. Gertz
@nl
prefLabel
Morie A Gertz
@ast
Morie A Gertz
@en
Morie A Gertz
@es
Morie A Gertz
@nl
Morie A. Gertz
@cs
Morie A. Gertz
@de
Morie A. Gertz
@sk
P106
P214
P21
P214
P31
P496
0000-0002-3853-5196
P5008
P569
1952-08-07T00:00:00Z